Overview

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants with Moderately Severe to Severe Diabetic Retinopathy (CAPRI).
Phase:
Phase 2
Details
Lead Sponsor:
Alkahest, Inc.